openPR Logo
Press release

Heal Your Heart

07-04-2016 12:58 PM CET | Health & Medicine

Press release from: Heal Your Heart

The Enhanced External Counter Pulsation (EECP) treatment, which helps treat cardiac patients non-surgically without risk, for the first time in the state.

"If you have heart disease, you probably know all about statins (cholesterol lowering medications) and beta blockers (Blood Pressure Medication), angioplasty and bypass surgery, and the benefits of regular exercise," explains Dr Ajith Joy. K, the chief executive officer.

"What is to be done when all these treatments fail or when someone is not eligible for the above treatments? About 30 per cent of all cardiac patients are in this category and they live on suffering with chest pain, mobility restriction, severe breathlessness, swelling on the feet, etc. The EECP could be an approved treatment method for them."

The idea behind this wacky-sounding treatment is to decrease the demand on an ailing heart by helping it push blood through the body.

According to the team of doctors at the Med.Links, the EECP diminishes the symptoms of ischemia.

In numerous studies, EECP has been shown to relieve angina, improve exercise tolerance, and decrease the degree of ischemia in a cardiac stress test.

For More Details Visit
http://www.healurheart.com

Heal Your Heart ™ (Vasomeditech EECP Center) is a Unit of Vaso-Meditech Pvt Ltd clinical division. Heal Your Heart centers are established across India for advance approved cardiology guideline recommended Non-Invasive Cardiac treatment. We are leaders in providing EECP treatment and cardiac rehabilitation program through qualified physicians and trained certified therapist under cardiologist supervision. Our unique Vasomeditech EECP treatment has shown to be efficient, safe and can be provided under day care facility.

Heal Your Heart
No.4/77, Thanthai Periyar Street, East Cost Road,
Neelankarai,
Chennai - 600 041

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Heal Your Heart here

News-ID: 347079 • Views:

More Releases for EECP

Refractory Angina Market to receive overwhelming hike in Revenues by 2025
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Refractory Angina Market Growth Framework 2025 | Ark Therapeutics Group plc, Neo …
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Refractory Angina Market Research Report 2017-2025 | Top Key Players : Ark Thera …
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Refractory Angina Market | Ark Therapeutics Group plc, Neovasc Inc., Saneron CCE …
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Refractory Angina Market Growth opportunities 2017-2025 : Saneron CCEL Therapeut …
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Refractory Angina Market Revenue, Opportunity, Segment and Key Trends 2025
In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows down and makes it